Drug Trial Radar · NCT00412061
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Last checked: Nov 19, 2026Latest source record: Nov 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
429
Actual
Start
Dec 2006
Primary completion
Apr 2010
Study completion Jun 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
Conditions
- Carcinoid Tumor
- Malignant Carcinoid Syndrome
Interventions
OctreotideDrug
Octreotide 30 mg intramuscularly (i.m.) every 28 days.
PlaceboDrug
A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
EverolimusDrug
A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Per Adjudicated Central Radiology ReviewTime frame: Time from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 10 January 2007, until cut-off date 02 April 2010
Locations
70 sites in 15 countries. Site status is shown where the registry gives one.
University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2)
Tucson, Arizona
Highlands Oncology Group The Center for Chest Care
Fayetteville, Arkansas
Hematology Oncology Services of Arkansas
Little Rock, Arkansas
Pacific Cancer Medical Center, Inc.
Anaheim, California
Cedars Sinai Medical Center SC-2
Los Angeles, California
University of California at Los Angeles UCLA New SC Address
Los Angeles, California
University of Colorado Dept. of Univ. of Colorado
Aurora, Colorado
Rocky Mountain Cancer Centers Dept of Rocky Mountain (2)
Denver, Colorado
Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO
Norwich, Connecticut
Cancer Centers of Connecticut Southington Location
Southington, Connecticut
Hematology Oncology PC Dept.of Hematology Oncology(2)
Stamford, Connecticut
Ocala Oncology Center Dept. of Ocala Oncology Center
Ocala, Florida
Cancer Care and Hematology Specialists of Chicagoland Niles
Niles, Illinois
Indiana University Dept.of IndianaUniv.CancerCtr
Indianapolis, Indiana
Central Indiana Cancer Centers CICC - South
Indianapolis, Indiana
University of Iowa Medical Center Internal Medicine
Iowa City, Iowa
University of Kansas Cancer Center Deptof Uof Kansas CancerCenter
Kansas City, Kansas
Kansas City Cancer Center KCCC Business Office
Overland Park, Kansas
Norton Cancer Institute Clinical Research Program
Louisville, Kentucky
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)
New Orleans, Louisiana
Mayo Clinic - Rochester Division of Hematology
Rochester, Minnesota
Washington University School Of Medicine-Siteman Cancer Ctr Division of Oncology
St Louis, Missouri
The Center for Cancer Care and Research
St Louis, Missouri
Dartmouth Hitchcock Medical Center Medical Oncology
Lebanon, New Hampshire
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
Albany, New York
New York University Medical Center NYU Medical Center (2)
New York, New York
Duke University Medical Center Dept. of Duke Cancer Center
Durham, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Cancer Centers of the Carolinas CC of C -Eastside
Greenville, South Carolina
Texas Oncology, P.A. Central Austin Cancer Center
Austin, Texas
South Texas Institute of Cancer S. Tex Inst.- Corpus Christi
Corpus Christi, Texas
Sammons Cancer Center - Texas Oncology Sammons Cancer Center (SC)
Dallas, Texas
Texas Oncology, P.A. Forth Worth -- 12th Avenue
Fort Worth, Texas
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
Houston, Texas
Tyler Cancer Center
Tyler, Texas
Virginia Oncology Associates VOA - Lake Wright
Norfolk, Virginia
Northwest Cancer Specialists Compass Oncology -BKM
Vancouver, Washington
University of Wisconsin / Paul P. Carbone Comp Cancer Center GI Oncology Research Center
Madison, Wisconsin
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.